SPDYE22P

Across TCGA pan-cancer cohorts, SPDYE22P RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated SPDYE22P data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SPDYE22P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SPDYE22P expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.

KIRC, KICH, and ACC are the cancer types where SPDYE22P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Tertile	All	0.495	0.686	<.001	170	view →
KICH	OS	Tertile	III,IV	0.162	0.808	.001	60	view →
ACC	OS	Tertile	All	0.145	0.705	.002	54	view →
COAD	DFS	Tertile	III,IV	0.333	0.745	<.001	51	view →
LIHC	OS	Tertile	All	0.473	0.712	<.001	51	view →
BRCA	OS	Tertile	All	0.483	0.606	.009	42	view →
UVM	DFS	Tertile	III,IV	0.132	0.704	<.001	36	view →
PAAD	DFS	Tertile	II,III,IV	0.238	0.462	<.001	21	view →
UCS	DFS	Quartile	III,IV	0.094	0.350	.033	18	view →
LUSC	OS	Tertile	IV	0.001	0.651	.025	18	view →
LGG	DFS	Tertile	All	0.289	0.443	.004	11	view →
STAD	OS	Quartile	II,III,IV	0.780	0.574	.012	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

SPDYE22P–KIRC (OS)

Open the KIRC breakdown →